Outlook Therapeutics, Inc. (OTLK)

NCM – Real vaqt narxi. Valyuta: USD

1.13

-0.01 (-0.44%)

Bozor ochiq: Aug 12, 2026, 1:13 PM EDT

1.13

-0.00 (-0.13%)

Oldingi bozordan keyin: Aug 11, 2026, 7:58 PM EDT

10.08.2026

OTLK Up More Than 300% in 3 Months: Here's What You Should Know

Outlook Therapeutics rallies 311.8% in three months as Lytenava's FDA approval boosts optimism ahead of its planned U.S. launch by year-end.

06.08.2026

Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Outlook Therapeutics, Inc. (OTLK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

06.08.2026

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

ISELIN, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it will report its financial results for the third quarter fiscal year 2026 and will host a corporate update conference call and webcast on Friday, August 14, 2026, at 8:30 AM ET.

03.08.2026

Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?

OTLK heads into Q3 results with investors watching European Lytenava sales, U.S. launch plans and updates after its landmark FDA approval.

Videolar

No Data

There is no data to display

Outlook Therapeutics, Inc. (OTLK)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Outlook Therapeutics, Inc. (OTLK)

OTLK Up More Than 300% in 3 Months: Here's What You Should Know

Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?

Videolar

No Data

OTLK Up More Than 300% in 3 Months: Here's What You Should Know

Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?

Videolar

No Data

Search stocks

Outlook Therapeutics, Inc. (OTLK)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Outlook Therapeutics, Inc. (OTLK)

OTLK Up More Than 300% in 3 Months: Here's What You Should Know

Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?

Videolar

No Data

OTLK Up More Than 300% in 3 Months: Here's What You Should Know

Outlook Therapeutics, Inc. (OTLK) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026

Outlook Therapeutics to Report Q3 Earnings: What's in the Cards?

Videolar

No Data